Thomasina Anderson Sharpe, MD
NPI 1023085669 · Family Medicine Physician · Mobile, AL
Enrolled with Medicare as Practitioner - Family Practice · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1023085669
- Entity type
- Individual
- Primary specialty
- Family Medicine PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Female
- Sole proprietor
- No
- License
- 18229 (AL)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,249 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Injection of Drug Or Substance Under Skin Or Into Muscle96372 | 285 | $12 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 250 | $114 |
| Respiratory Infectious Agent Detection By Rna for Severe Acute Respiratory Syndrome Coronavirus 2 (covid 19), Influenza A, Influenza B, and Respiratory Syncytial Virus, Upper Respiratory Specimen, Each Reported As Detected Or Not Detected0241U | 117 | $134 |
| Detection Test By Immunoassay With Direct Visual Observation for Influenza Virus87804 | 75 | $15 |
| Established Patient Office Or Other Outpatient Visit With High Level of Medical Decision Making, If Using Time, 40 Minutes Or More99215 | 72 | $158 |
| Detection Test By Immunoassay With Direct Visual Observation for Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 36 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Amoxicillin/Potassium Clavbrand: Amoxicillin-Clavulanate Potass | 173 | 160 |
| Cefdinir | 127 | 122 |
| Prednisone | 117 | 101 |
| Azithromycin | 73 | 68 |
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa | 69 | 62 |
| Nirmatrelvir/Ritonavirbrand: Paxlovid | 63 | 63 |
| Doxycycline Hyclate | 49 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$274 across 9 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-03-02
- Last updated
- 2026-04-16
- Certified
- 2026-04-16
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.